EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
Portfolio Pulse from Vandana Singh
Haystack Oncology, a Quest Diagnostics company, has entered a research collaboration with Lisata Therapeutics to use Haystack MRD technology in evaluating the efficacy of a pancreatic cancer therapy. Lisata will use this technology in a clinical study for its lead product candidate, certepetide, in patients with metastatic pancreatic cancer.
July 18, 2024 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quest Diagnostics' subsidiary, Haystack Oncology, has entered a research collaboration with Lisata Therapeutics to use its MRD technology in a clinical study for pancreatic cancer therapy.
The collaboration highlights the innovative use of Quest Diagnostics' subsidiary technology in a significant clinical study, potentially boosting investor confidence in DGX's growth and innovation capabilities.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Lisata Therapeutics has partnered with Haystack Oncology to use its MRD technology in a clinical study evaluating certepetide for metastatic pancreatic cancer.
The partnership and use of advanced MRD technology in a critical clinical study could enhance the perceived value of Lisata's research capabilities and its lead product candidate, potentially driving positive investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90